The Thoc1 Ribonucleoprotein as a Novel Biomarker for Prostate Cancer Treatment Assignment
Technical Report,15 Sep 2014,14 Sep 2015
Health Research, Inc., Roswell Park Division Buffalo United States
Pagination or Media Count:
Active surveillance AS is an option for men with low risk prostate cancer in order to reduce over treatment, but few men choose it because current prognostic indicators are imperfect. The objectives of this research are to test whether pThoc1 can improve the assignment of prostate cancer patients to therapy. We have made significant progress on the goals articulated in the Statement of Work. IRBHRPO approval has been obtained for construction and use of new TMAs PI Mohler and Goodrich. The TMAs from PCaP have been obtained PI Mohler and Goodrich. Pathology analysis of 1146 patient specimens is complete and construction of TMAs initiated PI Mohler. Optimization of TMA staining is complete and staining of TMAs initiated PI Goodrich. IRBHRPO approval for active surveillance specimens has been obtained PI Mohler, Goodrich. Enrollment of prostate cancer patients on active surveillance is ongoing PI Mohler. ELISA assays for measuring pThoc1 and pThoc1 autoantibodies have been successfully developed PI Goodrich. Analysis of serum samples from a mouse model of prostate cancer has been performed, establishing feasibility PI Goodrich. IRBHRPO approval for serum samples has been obtained PI Mohler, Goodrich. All preparative, optimization, and regulatory approval work has thus been completed, setting the stage for data gathering in year 2 of the grant. Over treatment complicates the clinical management of prostate cancer. Improving the ability to distinguish aggressive from indolent disease is recognized as an unmet need by the 2013 PCRP Overarching Challenges. Identifying pThoc1 as a biomarker that can help meet this need will have significant impact.